source
- Takeda releases additional Phase 3 data to bolster its orexin program amid new competitionTakeda announced new results from its two Phase 3 trials of an orexin‑targeting therapy. The data are intended to demonstrate the drug’s efficacy and safety, reinforcing Takeda’s claim of market‑l…
- Elicio Therapeutics’ KRAS pancreatic cancer vaccine fails in Phase 2, stock drops sharplyElicio Therapeutics reported that its KRAS‑targeted vaccine for pancreatic cancer did not improve patient outcomes in a mid‑stage (Phase 2) trial. The study results were released in a company state…